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Summary
Background.  —  General  practitioners  (GPs)  play  a  pivotal  role  in  the  long-term  management  of
patients with  atrial  ﬁbrillation  (AF),  including  anticoagulant  prophylaxis  for  stroke  prevention.
Aims. —  To  investigate  the  antithrombotic  prescription  behaviours  of  GPs  in  France  and  compare
them with  the  European  Society  of  Cardiology  (ESC)  guidelines  for  stroke  prevention,  and  to
identify the  major  determinants  of  use  of  antithrombotic  therapy.
Methods.  —  We  conducted  a  cross-sectional  survey,  using  data  from  the  French  Longitudinal
Patient Database,  on  the  use  of  antithrombotic  treatments  for  stroke  prevention  in  15,623
patients (≥  18  years  of  age)  with  AF  who  attended  at  least  one  GP  consultation  between  July
2010 and  June  2011.  Data  were  collected  on  patient  baseline  characteristics,  stroke  risk  factors,
and prescription  of  antithrombotic  drugs.
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Results.  —  The  mean  age  was  74.6  ±  11.1  years,  59.5%  were  men,  and  83.1%  had  a  CHADS2
score  ≥  1.  Over  half  (52.6%)  of  the  patients  with  a  CHADS2 score  ≥  1  received  a  vitamin  K  antag-
onist (alone  or  in  combination  with  an  antiplatelet),  19.3%  received  aspirin  alone,  and  23.4%
received no  antithrombotic  therapy;  3.6%  of  the  patients  received  dual  antiplatelet  therapy
and 1.1%  clopidogrel  alone.  Over  half  of  the  patients  (56.3%)  were  treated  in  accordance  with
the ESC  2010  guidelines.  Of  the  remaining  patients,  19.4%  received  no  treatment,  13.0%  were
inadequately  treated,  and  11.2%  were  over-treated.  Factors  associated  with  antithrombotic
treatment  were  anti-arrhythmic  therapy,  higher  stroke  risk,  presence  of  atherothrombotic  dis-
ease, and  use  of  non-steroidal  anti-inﬂammatory  drugs.  Female  gender  was  associated  with  a
lower likelihood  of  antithrombotic  treatment.
Conclusions.  —  In  this  large  French  study,  approximately  45%  of  thromboembolic  high-risk
patients were  either  not  treated  or  inadequately  treated.  Better  compliance  with  evidence-
based guidelines  is  needed  to  reduce  the  burden  of  stroke  in  the  AF  population.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  Les  médecins  généralistes  jouent  un  rôle  clé  dans  la  prise  en  charge  au  long  cours
des patients  présentant  une  ﬁbrillation  atriale  (FA),  notamment  dans  la  gestion  des  traitements
antithrombotiques.
Méthodes.  —  Nous  avons  conduit  une  étude  épidémiologique,  à  partir  d’une  base  de  données
franc¸aise avec  suivi  longitudinal,  centrée  sur  la  stratégie  thérapeutique  pour  15  623  patients
(âgés ≥  18  ans)  présentant  une  FA,  et  bénéﬁciant  d’au  moins  une  consultation  en  médecine
générale  entre  juillet  2010  et  juin  2011.  Les  données  recueillies  concernaient  les  caractéris-
tiques cliniques  des  patients  au  début  de  la  période  d’étude,  les  facteurs  de  risque  d’accident
vasculaire cérébral  (AVC),  et  les  prescriptions  d’antithrombotiques.
Résultats.  —  L’âge  moyen  était  de  74,6  ±  11,1  ans,  avec  59,5  %  d’hommes,  83,1  %  des
patients ayant  un  score  CHADS2 ≥  1.  Plus  de  la  moitié  (52,6  %)  des  patients  avec  un  score
CHADS2 ≥  1  bénéﬁciait  d’un  traitement  par  un  antivitaminique  K  (seul  ou  associé  à  un  antiagré-
gant), 19,3  %  étaient  sous  aspirine  en  monothérapie,  et  23,4  %  ne  recevaient  aucun  traitement
antithrombotique  ;  3,6  %  des  patients  étaient  sous  bithérapie  antiagrégante  plaquettaire,  1,1  %
sous clopidogrel  seul.  Une  faible  majorité  des  patients  (56,3  %)  étaient  traités  selon  les  recom-
mandations  de  2010  de  l’ESC.  Pour  les  autres  patients,  19,4  %  ne  recevaient  aucun  traitement,
13,0 %  étaient  insufﬁsamment  traités,  et  11,2  %  étaient  « surtraités  » par  rapport  aux  recom-
mandations.  Les  facteurs  associés  à  la  prescription  d’anticoagulants  étaient  la  prescription
d’anti-arythmiques,  un  risqué  élevé  d’AVC,  la  présence  d’une  atteinte  athérothrombotique
et l’emploi  d’anti-inﬂammatoire  non  stéroïdien.  Le  sexe  féminin  était  associé  à  une  moindre
prescription  d’anticoagulants.
Conclusions.  —  Au  sein  de  cette  large  cohorte  franc¸aise,  environ  45  %  des  patients  en  FA  à  haut
risque thromboembolique  ne  sont,  soit  pas  traités,  soit  traités  sans  respect  des  recommanda-
tions. Une  meilleure  application  des  recommandations  sur  la  prise  en  charge  de  la  FA  semble
indispensable  pour  réduire  les  accidents  ischémiques  cérébraux  au  sein  de  cette  population.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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oIntroduction
Atrial  ﬁbrillation  (AF)  is  the  most  common  cardiac  arrhyth-
mia  and  is  frequently  encountered  in  the  primary  care
setting.  The  lifetime  risk  for  developing  AF  or  atrial  ﬂut-
ter  at  40  years  of  age  is  estimated  to  be  26%  for  men  and
23%  for  women  [1].  AF  affects  between  600,000  and  1  mil-
lion  patients  in  France  [2,3].  Given  the  ageing  population
and  the  increasing  prevalence  of  risk  factors  for  AF,  includ-
ing  hypertension,  heart  failure,  older  age,  diabetes  mellitus
and  vascular  disease  [4],  the  burden  of  AF  in  western
o
b
Wopulations  is  predicted  to  rise  to  epidemic  proportions  by
050  [5].
Patients  with  AF  are  at  increased  risk  of  throm-
otic  events,  including  stroke  and  systemic  embolism.
vidence-based  guidelines  recommend  individualized  risk
tratiﬁcation  with  validated  tools  and  the  use  of  oral  antico-
gulant  (OAC)  therapy  for  those  identiﬁed  to  be  at  moderate
r  high  risk  of  stroke  [6,7].  For  more  than  six  decades,  the
nly  oral  anticoagulants  available  for  long-term  use  have
een  the  vitamin  K  antagonists  (VKAs;  e.g.  warfarin)  [8].
hile  effective  in  preventing  thromboembolism,  VKAs  have
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everal  drawbacks,  including  food  and  drug  interactions,  a
arrow  therapeutic  range,  and  wide  variations  in  response  to
reatment  that  necessitate  close  laboratory  monitoring  and
requent  dose  adjustments  [9].  Anticoagulant  therapy  also
arries  a  risk  of  bleeding,  with  potentially  catastrophic  con-
equences  in  the  event  of  intracranial  haemorrhage  [10].  In
n  analysis  from  the  United  States,  65%  of  emergency  hospi-
alizations  (between  2007  and  2009)  in  older  adults  were
ue  to  unintentional  drug  overdoses,  one-third  of  which
ere  associated  with  warfarin  therapy  [11].  Consequently,
bservational  studies  have  shown  that  a  large  percentage
f  eligible  patients  at  risk  of  stroke  do  not  receive  antico-
gulant  therapy  [12,13].  Conversely,  a  sizable  proportion  of
F  patients  at  low  risk  receive  inappropriate  treatment  with
n  oral  anticoagulant,  placing  them  at  unnecessary  risk  of  a
leed  [12,13].
In  France,  anticoagulant  prophylaxis  for  patients  with
F  is  managed  largely  in  the  primary  care  setting.  General
ractitioners  (GPs)  play  a  pivotal  role  in  the  long-term  man-
gement  of  these  patients.  Adherence  to  practice  guidelines
or  stroke  prevention  and  effective  collaboration  between
Ps  and  cardiologists,  or  other  specialists,  are  therefore
ssential.  In  this  analysis,  we  investigated  the  antithrom-
otic  prescription  behaviours  of  GPs  in  France  and  compared
hem  with  the  recommendations  in  the  2010  and  2012
uropean  Society  of  Cardiology  (ESC)  guidelines  for  stroke
revention  in  AF  [6,7].  We  also  identiﬁed  the  major  deter-
inants  of  use  of  antithrombotic  therapy.
ethods
sing  data  from  the  French  Longitudinal  Patient  Database
LPD;  Cegedim  Strategic  Data,  France),  a  medical  records
nd  prescriptions  database  [14],  we  conducted  a cross-
ectional  survey  on  the  use  of  antithrombotic  treatments
or  stroke  prevention  in  patients  with  AF.  Since  1994,  the
PD  has  collected  anonymized  data  from  more  than  1.6
illion  patients  though  a  computerized  network  of  1200
fﬁce-based  GPs.  The  panel  of  physicians  is  representative
f  French  GPs  in  terms  of  their  age,  sex,  and  geography.  GPs
o  not  receive  direct  compensation  for  participating  in  the
atabase.  The  Commission  Nationale  de  l’Informatique  et
es  Libertés  approved  the  use  of  the  LPD  data  for  analysis
nd  patient  informed  consent  was  not  required.
tudy population and data extracted
he  study  population  comprised  adults  (≥  18  years  of  age)
ith  a  diagnosis  of  AF  who  attended  at  least  one  GP  consul-
ation  between  1  July  2010  and  30  June  2011.  During  this
eriod,  data  were  collected  on  patient  baseline  characteris-
ics,  risk  factors  for  stroke  (i.e.  congestive  heart  failure,  left
entricular  dysfunction,  hypertension,  diabetes  mellitus,
troke,  transient  ischaemic  attack,  systemic  embolism,  vas-
ular  pathology),  and  prescription  of  VKAs  and  antiplatelet
rugs.
valuation of stroke riskach  patient’s  risk  of  stroke  was  evaluated  retrospectively
sing  the  CHADS2 (congestive  heart  failure,  hyperten-
ion,  age  >  75  years,  diabetes  mellitus,  and  prior  stroke  or
O
r
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ransient  ischaemic  attack  [doubled])  criteria.  A  CHADS2
core  of  0  was  taken  as  indicative  of  low  risk,  1  as  moderate
isk,  and  ≥  2  as  high  risk.  In  addition,  the  patients’  CHA2DS2-
ASc  (cardiac  failure  or  dysfunction,  hypertension,  age  ≥  75
doubled],  diabetes,  stroke  [doubled]-vascular  disease,  age
5—74,  and  sex  category  [female])  scores  were  calculated,
ith  the  caveat  that  this  score  was  included  in  the  2012
SC  guidelines  [15],  and  was  not  therefore  incorporated
nto  normal  practice  at  the  time  the  data  were  collected.
reatment  with  antithrombotic  drugs  for  stroke  prevention
n  AF  (VKAs  and  antiplatelets)  was  evaluated  according  to
he  2010/2012  ESC  guideline  recommendations  [6,7].  Inad-
quate  treatment  was  deﬁned  as  the  use  of  aspirin  instead  of
AC  in  moderate-  to  high-risk  patients  and  over  treatment
as  deﬁned  as  the  use  of  OAC  instead  of  aspirin  in  low-risk
atients.
tatistical analysis
ontinuous  variables  are  expressed  as  mean  ±  standard
eviation  (SD)  and  categorical  variables  as  frequency  (per-
entage).  The  choice  of  treatment  with  VKA  alone,  aspirin
lone,  or  VKA  plus  aspirin  was  studied  in  a  binary  man-
er  (treatment  vs.  no  treatment).  Potential  determinants  of
reatment  (vs.  no  treatment)  were  identiﬁed  from  patient
aseline  and  disease  characteristics,  medical  history,  and
oncomitant  treatments.  The  analysis  was  performed  using
he  GLIMMIX  (SAS  9.2,  SAS  Institute  Inc.,  Cary,  NC,  USA)
rocedure  [16]  for  multivariable  analysis,  with  the  variable
‘physician’’  taken  as  a  random  effect.  Factors  associated
ith  treatment  (vs.  no  treatment)  that  were  signiﬁcant
t  the  20%  threshold  in  univariate  analysis  were  included
n  a  backwards  elimination  multivariable  logistic  regres-
ion  model;  factors  signiﬁcant  at  the  0.001  level  were
etained  in  the  ﬁnal  model.  All  pairwise  interactions  were
ested.  CHADS2 or  CHA2DS2-VASc  scores  were  introduced  into
he  ﬁnal  models  to  determine  whether  they  were  major
eterminants  of  antithrombotic  therapy  use.  Results  are
resented  with  odds  ratios  (ORs)  and  their  95%  conﬁdence
ntervals  (CIs).
esults
tudy population
 total  of  15,623  patients  with  AF  were  identiﬁed.  The
ean  age  was  74.6  ±  11.1  years,  59.5%  were  men,  and  5.1%
ad  valvular  disease  (Table  1).  The  overall  mean  body  mass
ndex  (BMI)  was  27.9  ±  5.3  kg/m2;  27.9%  of  the  patients  had
 BMI  between  20  and  25  kg/m2 and  4.1%  had  a  BMI  below
0  kg/m2.  Of  the  patients  in  whom  the  type  of  AF  was  known,
7.4%  had  paroxysmal  AF,  2.7%  had  persistent  AF  and  20.0%
ad  permanent  AF.  The  mean  CHADS2 score  was  1.5  ±  1.1
nd  83.1%  had  a  CHADS2 score  ≥  1.  The  mean  CHA2DS2-VASc
core  was  2.9  ±  1.5  and  93.6%  had  a  CHA2DS2-VASc  score  ≥  1.
ntithrombotic treatment in patients at  risk of
trokever  half  (52.6%)  of  the  patients  with  a  CHADS2 score  ≥  1
eceived  a  VKA  (alone  or  in  combination  with  an
ntiplatelet),  19.3%  received  aspirin  alone,  and  23.4%
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Table  1  Patient  characteristics,  treatments,  and  risk  level  for  stroke,  overall  and  according  to  use  of  antithrombotic
therapy  at  inclusion.
Variable  All  patients
(n =  15,623)
No
antithrombotic
therapy  (n  =  3924)
Antithrombotic
therapy
(n  =  11,699)
Men  9291  (59.5)  2115  (53.9)  7176  (61.3)
Age  (years)  74.6  ±  11.1  74.2  ±  13.1  74.7  ±  10.4
Age  ≥  75  (years) 8981  (57.5) 2265  (57.7)  6716  (57.4)
Body  mass  index  (kg/m2)a 27.9  ±  5.3 26.9  ±  5.0 28.1  ±  5.4
Systolic  blood  pressure  (mmHg)b 133  ±  15 133  ±  16 133  ±  15
Diastolic  blood  pressure  (mmHg)c 76  ±  9 76  ±  10 76  ±  9
Medical  history
Arterial  hypertension  9246  (59.2)  1934  (49.3)  7312  (62.5)
Diabetes  mellitus  2683  (17.2)  513  (13.1)  2170  (18.5)
Heart  failure  1775  (11.4)  347  (8.8)  1428  (12.2)
Stroke  763  (4.9) 157  (4.0)  606  (5.2)
TIA  502  (3.2) 82  (2.1) 420  (3.6)
Systemic  embolism 97  (0.6) 8  (0.2) 89  (0.8)
Myocardial  infarction 665  (4.3) 108  (2.8) 557  (4.8)
Prosthetic  heart  valve 309  (2.0) 54  (1.4) 255  (2.2)
Neurological  disorders 422  (2.7) 134  (3.4) 288  (2.5)
PAD 827  (5.3) 138  (3.5) 689  (5.9)
Valvular  disease 795  (5.1) 186  (4.7) 609  (5.2)
Type  of  AFd
Paroxysmal 1891  (77.4) 513  (84.0) 1378  (75.2)
Permanent 488  (20.0) 88  (14.4) 400  (21.8)
Persistent  65  (2.7)  10  (1.6)  55  (3.0)
Concomitant  drugs
Non-steroidal  anti-inﬂammatory  drug  7492  (48.0)  1305  (33.3)  6187  (52.9)
Anti-arrhythmic  drug  7425  (47.5)  834  (21.3)  6591  (56.3)
Injectable  anticoagulants  (e.g.  heparin)  482  (3.1)  83  (2.1)  399  (3.4)
Risk  scores  for  stroke
CHADS2 score  (%)
0  2638  (16.9)  887  (22.6)  1751  (15.0)
1  5026  (32.2)  1342  (34.2)  3684  (31.5)
≥  2  7959  (50.9)  1695  (43.2)  6264  (53.5)
CHA2DS2-VASc  score  (%)
0  998  (6.4)  399  (10.2)  599  (5.1)
1  1774  (11.4)  499  (12.7)  1275  (10.9)
≥  2  12,851  (82.3)  3026  (77.1)  9825  (84.0)
Percentages were calculated on the basis of the total number of known data. Values are given as number (%) or mean ± SD.
a Available for 8390 patients.
b Available for 12,932 patients.
c Available for 12,926 patients.
d Available for 2444 patients.
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dreceived  no  antithrombotic  therapy  (Fig.  1).  A  small  per-
centage  of  patients  received  dual  antiplatelet  therapy
(3.6%)  and  1.1%  received  clopidogrel  alone.
Over  half  of  the  patients  (56.3%)  were  treated  in  accor-
dance  with  the  recommendations  in  the  ESC  2010  guidelines
[6]  (Fig.  2A).  Of  the  remaining  patients,  19.4%  of  patients
received  no  treatment,  13.0%  were  inadequately  treated,
and  11.2%  of  patients  were  over-treated.  In  patients  with  a
CHADS2 score  of  0,  who  are  at  low  risk  of  a  stroke  and  do  not
require  OAC  prophylaxis,  66.4%  were  over-treated  (Fig.  2A).
Patients  with  a  CHADS2 score  of  1  were  the  most  likely  of
any  of  the  risk  groups  to  receive  guideline-recommended
t
w
p
therapy  (70.4%).  Over  half  (54.9%,  n  =  4372)  of  those
t  highest  risk  (CHADS2 score  ≥  2)  and  52.4%  (n  =  6740)
ith  a CHA2DS2-VASc  ≥  2  received  anticoagulant  therapy
Fig.  2A,  2B).
In terms  of  the  ESC  2012  guidelines  [7],  which  advocate
he  CHA2DS2-VASc  score  for  risk  stratiﬁcation,  the  proportion
f  patients  who  received  guideline-recommended  therapies
ecreased  for  patients  with  a  score  of  1  or  ≥  2  compared  with
he  ESC  2010  recommendations  (Fig.  2B).  This  difference
as  due  largely  to  a  higher  rate  of  inadequate  treatment  in
atients  at  moderate  risk,  and  to  higher  rates  of  inadequate
reatment  or  no  treatment  in  those  at  high  risk.
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aigure 1. Antithrombotic use in patients with a CHADS2 score ≥ 1
n = 12,985).
actors associated with antithrombotic
reatment
he  strongest  factor  associated  with  antithrombotic  treat-
ent  was  the  use  of  anti-arrhythmic  therapy  (Tables  2
nd  3).  Higher  stroke  risk,  presence  of  atherothrombotic
isease,  and  use  of  non-steroidal  anti-inﬂammatory  drugs
ere  also  associated  with  greater  likelihood  of  antithrom-
otic  therapy  use  whereas  female  gender  was  associated
ith  a  lower  likelihood.
iscussion
hese  nationwide  French  data  indicate  that  over  four-ﬁfths
f  AF  patients  treated  in  the  primary  care  setting  are  at
oderate  to  high  risk  of  a  stroke  and  should  be  consid-
red  for  anticoagulant  treatment.  A  large  percentage  of  the
atients  at  high  risk  are  inadequately  treated,  leaving  them
nprotected  against  a  thromboembolic  event,  and  many  of
hose  at  low  risk  are  over-treated,  placing  them  at  unnec-
ssary  risk  of  a  treatment-associated  bleeding  event.  These
ndings  indicate  a  treatment  gap  between  the  recommen-
ations  in  practice  guidelines  [6,7]  and  everyday  clinical
ractice.
omparison with other studies
ur  ﬁndings  are  in  concert  with  some  studies,  which  indi-
ate  disappointing  rates  of  OAC  use  for  stroke  prevention  in
he  AF  population  [12,13,17].  They  are  also  much  lower  than
he  rates  reported  in  other  studies,  such  as  the  French  Euro-
ean  Public  Health  Alliance  (EPHA)  study  (83.4%  on  VKAs)
18],  the  Prevention  of  thromboembolic  events  —  European
egistry  in  Atrial  Fibrillation  (PREFER  in  AF)  registry  (>  80%
n  OACs)  [19],  the  EURObservational  Research  Programme-
trial  Fibrillation  General  Registry  Pilot  Phase  (EORP-AF
ilot)  registry  (approximately  78%  on  OACs)  [20],  the  Ger-
an  Outpatient  Registry  Upon  Morbidity  of  Atrial  Fibrillation
ATRIUM)  (82.7%  on  OAC)  [21],  the  Outcomes  Registry  for
etter  Informed  Treatment  of  Atrial  Fibrillation  (ORBIT-AF)
83.0%  of  patients  without  contraindications  to  OAC)  [22],
nd  a  cross-sectional  study  conducted  in  the  Netherlands
69%  on  OAC)  [23].  Several  key  reasons  can  be  proposed
or  these  variations  in  practice  patterns.  The  ﬁrst  concerns
he  proﬁle  of  the  study  population,  as  the  characteristics
nd  risk  proﬁles  of  patients  in  hospital  registries  differ  from
B
O
bigure 2. Anticoagulant prescription behaviours of GPs in France
ased on (A) CHADS2 score (ESC 2010 recommendations [6]) and (B)
HA2DS2-VASc score (ESC 2012 recommendations [7]).
hose  of  outpatients  in  general  practice.  The  second  con-
erns  provider  specialty  and  treatment  setting,  with  higher
evels  of  OAC  use  provided  by  specialists  versus  primary
are/internal  medicine  providers  [24]  and  better  adherence
o  evidence-based  guidelines  in  hospitals  versus  non-hospital
ettings  [25].  The  third  concerns  the  methodology  adopted.
rospectively  enrolled  patients  in  observational  studies  are
ubject  to  selection  bias.  In  contrast,  the  present  study  was
ased  on  a  primary  care  database  and  presents  a  ‘‘pure’’
iew  of  everyday  practice  patterns,  as  neither  the  physician
or  the  patient  was  aware  of  the  study  at  the  time  of  the
onsultation.  Furthermore,  the  management  of  anticoagu-
ants  in  France,  including  dosing  in  relation  to  international
ormalized  ratio  for  patients  on  VKAs,  is  conducted  by  GPs,
hereas  in  other  European  countries  such  patients  may
ttend  specialized  anticoagulation  clinics.arriers to anticoagulation
ften  patients  are  not  treated  according  to  guidelines
ecause  of  the  physician’s  perception  of  their  individual
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Table  2  Factors  associated  with  antithrombotic  treatment  in  atrial  ﬁbrillation,  with  CHADS2 score  forced  into  the  model
(based  on  data  from  all  15,623  patients).
Factor  OR  (95%  CI)  P  value
Anti-arrhythmic  (ref:  no  anti-arrhythmic) 4.70  (4.30—5.14)  <  0.0001
CHADS2 score  (ref:  score  of  0)
≥  2  2.13  (1.91—2.38)  <  0.0001
1  1.52  (1.36—1.70)  <  0.0001
NSAID  (ref:  no  NSAID)  2.09  (1.92—2.27)  <  0.0001
Atherothrombotic  diseasea (ref:  no  atherothrombotic  disease)  1.48  (1.30—1.70)  <  0.0001
Female  sex  (ref:  male)  0.65  (0.60—0.70)  <  0.0001
CI: conﬁdence interval; NSAID: non-steroidal anti-inﬂammatory drug; OR: odds ratio.
a Peripheral artery disease, systemic embolism, myocardial infarction, stroke or transient ischaemic attack.
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orisk  of  stroke  (or  haemorrhage),  which  may  be  at  variance
to  the  level  indicated  by  validated  risk  scores  [12,26—28].
Women  are  at  increased  risk  of  stroke  when  compared  with
men  [29],  yet  female  sex  was  associated  with  lower  rates
of  OAC  use  in  our  study.  Current  data  also  suggest  that
OAC  use  varies  according  to  the  type  of  treating  physi-
cian,  with  higher  rates  of  use  in  patients  treated  by  a
cardiologist  or  electrophysiologist  versus  a  primary  care
physician  [24].  Use  of  OAC  was  high  among  AF  patients
treated  by  cardiologists  in  the  EPHA  study  [18]  and  the
EORP-AF  Pilot  registry  [20].  In  contrast,  much  lower  rates
are  reported  in  studies,  such  as  the  Global  Anticoagulant
Registry  in  the  FIELD-Atrial  Fibrillation  (GARFIELD-AF)  [12],
which  reﬂects  management  across  the  spectrum  of  care
settings  treating  the  AF  community,  including  ofﬁce-based
specialists,  hospital  departments,  anticoagulant  clinics,  and
general  or  family  practice  settings.  Furthermore,  the  rec-
ommendation  to  use  risk  stratiﬁcation  schemes,  such  as
CHADS2 and  CHA2DS2-VASc  to  determine  risk  level  is  rel-
atively  recent  and  it  appears  likely  that  hospital-based
physicians  are  more  accepting  of  the  value  of  practice  guide-
lines  than  are  physicians  involved  in  outpatient  care  [25].
While  the  recommendations  for  prevention  of  thromboem-
bolism  in  patients  with  a  score  ≥  2  (whether  by  CHADS2
or  CHA2DS2-VASc)  are  clear,  the  situation  in  patients  with
a  score  of  1  is  more  complex,  with  physicians  facing
further  choices  regarding  the  optimal  treatment  strategy
(Table  4).
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Table  3  Factors  associated  with  antithrombotic  treatment  in  
model  (based  on  data  from  all  15,623  patients).
Factor  
Anti-arrhythmic  (ref:  no  anti-arrhythmic)  
CHA2DS2-VASc  score  (ref:  score  of  0)
≥2  
1  
NSAID  (ref:  no  NSAID)
Atherothrombotic  diseasea (ref:  no  atherothrombotic  disease)
Female  sex  (ref:  male)
CI: conﬁdence interval; NSAID: non-steroidal anti-inﬂammatory drug; O
a Peripheral artery disease, systemic embolism, myocardial infarction,nticoagulant treatments for stroke
revention
ACs  for  stroke  prevention  have  been  limited  to  VKAs,  such
s  warfarin,  for  over  six  decades  [8]. A  meta-analysis  of
9  clinical  trials  in  28,044  participants  demonstrated  that
djusted-dose  warfarin  reduced  the  risk  of  stroke  by  64%
95%  CI  49—74)  was  more  effective  than  antiplatelet  ther-
py  for  stroke  prevention  (relative  risk  reduction  39%,  95%
I  22—52),  and  absolute  increases  in  major  extracranial  hae-
orrhage  were  small  (≤  0.3%  per  year)  [30].  However,  the
ate  of  major  haemorrhage  in  practice  may  be  much  higher,
s  suggested  by  data  from  a  population-based  cohort  sur-
ey  of  more  than  125,000  warfarin-treated  patients  (3.8%,
5%  CI  3.8—3.9),  particularly  during  the  ﬁrst  month  of  treat-
ent  (11.8%,  95%  CI  11.1—12.5)  [31].  One  of  the  major
imitations  of  VKA  therapy  is  difﬁculty  maintaining  the  target
nternational  normalized  ratio  (2—3)  [19,32].  Recently  pub-
ished  data  from  the  LPD  indicated  that  <  50%  of  patients
ith  AF  in  France,  Germany  and  Italy  had  well-controlled
KA  treatment  (deﬁned  as  a time  in  therapeutic  range  >  70%)
33]. This  may  be  partly  due  to  the  substantial  difﬁculties
atients  experience  adhering  to  the  warfarin  regimen,  with
ne  study  reporting  that  36%  of  patients  miss  >  20%  of  their
oses  [34].  Suboptimal  anticoagulation  with  VKAs  is  associ-
ted  with  an  increased  risk  of  stroke,  particularly  during  the
rst  30  days  [32,35].  Concern  over  treatment-related  bleed-
ng  complications,  especially  in  the  elderly  [36], is  in  part
atrial  ﬁbrillation,  with  CHA2DS2-VASc  score  forced  into  the
OR  (95%  CI)  P  value
4.72  (4.31—5.16)  <  0.0001
3.11  (2.66—3.64)  <  0.0001
2.09  (1.74—2.51)  <  0.0001
2.10  (1.93—2.28)  <  0.0001
1.50  (1.30—1.72) <  0.0001
0.58  (0.53—0.63)  <  0.0001
R: odds ratio.
 stroke or transient ischaemic attack.
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Table  4  ESC  recommendations  for  antithrombotic  therapy  in  patients  with  AF.
Risk  score  ESC  AF  guidelines  2010  [6]  ESC  AF  guideline  update  2012  [7]
Non-valvular  AF
CHADS2 0  No  antithrombotic  therapy  (or
aspirin)  (Class  I,  level  of  evidence  B)
Strong  recommendation  to  use  the
CHA2DS2-VASc  risk  score  to  focus  on
identiﬁcation  of  ‘‘truly  low-risk’’
patients  with  non-valvular  AF
CHADS2 1 OAC  (Class  I,  level  of  evidence  A)  or
aspirin  (Class  I,  level  of  evidence  B)
CHADS2 ≥  2  OAC  (Class  I,  level  of  evidence  A)
CHA2DS2-VASc  0  No  antithrombotic  therapy
(preferred)  or  aspirin
No antithrombotic  therapy  (Class  I,  level
of  evidence  B)
CHA2DS2-VASc  1  OAC  (preferred)  or  aspirin  OAC  should  be  considered  according  to
individual  risk  and  patient  preference
(Class  IIa,  level  of  evidence  A)
No  antithrombotic  therapy  in
women  <  65  years  with  lone  AF  (i.e.  no
other  risk  factors  for  thromboembolism)
(Class  IIa,  level  of  evidence  B)
CHA2DS2-VASc  ≥  2  OAC  OAC  (Class  I,  level  of  evidence  A)  in
patients  without  contraindications
AF  and  valvular  heart
disease
Term Valvular  heart  disease Valvular  AF  (i.e.  AF  related  to  rheumatic
valvular  disease  [predominantly  mitral
stenosis]  or  prosthetic  heart  valves)
Risk  assessment  and
antithrombotic  therapy
OAC  in  patients  with  mitral  stenosis
and  AF  (Class  I,  level  of  evidence  C)
OAC  in  patients  with  clinically
signiﬁcant  mitral  regurgitation  (Class
I,  level  of  evidence  C)
Assess  each  patient’s  risk  of  stroke  using
the  CHA2DS2-VASc  score  and  treat  as  for
non-valvular  AF
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tesponsible  for  the  failure  to  provide  adequate  prophylaxis.
n  analysis  from  the  UK  General  Practice  Research  Database
emonstrated  that  30%  of  patients  starting  warfarin  therapy
iscontinue  the  medication  within  12  months  [37].  Conse-
uently,  substantial  efforts  have  been  made  over  the  past
ecade  to  identify  OACs  that  overcome  some  of  the  limi-
ations  of  VKAs  and  that  have  at  least  equivalent  efﬁcacy,
ith  a  reduced  risk  of  bleeding,  and  are  more  convenient
o  use  for  both  patients  and  physicians  [38]. This  research
as  led  to  the  introduction  of  the  non-VKA  oral  anticoagu-
ants  (NOACs),  comprising  the  oral  direct  thrombin  inhibitor
abigatran  and  the  direct  factor  Xa  inhibitors  rivaroxaban
nd  apixaban.  Edoxaban  has  been  approved  recently  by  the
S  Food  and  Drug  Administration  (FDA),  but  is  not  currently
vailable  on  the  market.  These  treatments  have  at  least  sim-
lar  efﬁcacy  to  VKAs,  with  predictable  pharmacokinetics,  a
table  dose-related  treatment  effect,  and  few  drug  inter-
ctions,  enabling  ﬁxed  dosing  without  the  need  for  regular
aboratory  monitoring  [39,40].
In  response  to  the  clinical  trial  evidence  demonstrating
heir  net  clinical  beneﬁt,  the  2012  ESC  guidelines  recom-
end  NOACs  over  adjusted-dose  VKAs  (Class  IIa,  level  of
vidence  A)  for  most  patients  age  65  years  or  older  with
on-valvular  AF  [7].  In  France,  economic  evaluations  have
emonstrated  that  NOACs  are  an  efﬁcient  alternative  to
arfarin  in  patients  with  non-valvular  AF  who  are  eligible
s
i
t
ror  stroke  prevention  [41,42]. NOACs  also  present  a  sug-
ested  option  in  patients  with  poorly  controlled  VKAs,  for
harmacological  reasons  and  based  on  epidemiological  data,
fter  a  cautious  evaluation  of  patient  compliance  by  the
P  or  cardiologist.  The  ESC  Working  Group  on  Thrombo-
is  recommends  using  a  decision-making  tool  (sex  female,
ge  <  60  years,  medial  history  [more  than  two  comorbidi-
ies],  treatment  [interacting  drugs,  e.g.  amiodarone  for
hythm  control],  tobacco  use  [doubled],  race  [doubled];
AMe-TT2R2)  to  identify  patients  likely  to  do  well  on  VKAs
score  of  0—2)  and  those  more  likely  to  have  poor  anticoag-
lation  control  (score  >  2)  who  would  probably  beneﬁt  from
tarting  a  NOAC  as  the  initial  therapy  [8].
trategies to improve adherence to guidelines
he  European  guidelines  on  AF  [6]  were  published  midway
hrough  2010,  with  an  update  in  2012  [7]  (Table  4).  Our
ata  reﬂect  practices  taking  place  during  2010  and  2011
nd  do  not  take  into  account  the  inevitable  ‘‘lag’’  that
ccurs  between  publication  of  guidelines  and  implementa-
ion  in  practice.  Assuming  that  sufﬁcient  time  has  elapsed
ince  the  publication  of  these  guidelines,  we  would  antic-
pate  and  hope  that  current  practice  more  closely  mirrors
he  recommendations  in  these  guidelines.  To  act  on  such
ecommendations,  however,  physicians  need  to  be  aware  of
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the  real  risk  of  stroke  in  their  AF  patients  and  be  convinced
that  the  guidelines  are  based  on  compelling  evidence  from
well-designed  controlled  clinical  trials.  Furthermore,  recent
data  indicate  that  NOACs  are  indeed  being  incorporated
into  clinical  practice,  but  there  is  as  yet  no  indication  that
the  overall  rates  of  OAC  use  are  improving  [43,44].  There
remains,  therefore,  an  urgent  need  to  address  the  barriers
to  optimal  OAC  use  and  persistence  in  the  AF  population.  In
France,  stroke  physicians  launched  a  national  action  plan
entitled  ‘‘Stroke  2010—2014’’,  the  aim  of  which  was  to
develop  stroke  care  networks  and  strategies  for  prevention
and  health  education  [45].  The  plan  is  now  shared  with  other
health  professionals,  and  more  recently  with  administrators
and  politicians.
A  think-tank,  comprising  leaders  from  academia,  govern-
ment,  industry  and  professional  societies,  was  convened  in
the  United  States  in  2012  to  identify  strategies  to  improve
stroke  prevention.  Their  recommendations  are  wide  ran-
ging,  and  encompass  the  identiﬁcation  of  reasons  for  OAC
underuse,  educational  initiatives  that  will  raise  awareness
of  stroke  risk  and  the  beneﬁts  of  OAC  treatment,  the  provi-
sion  of  decision-making  tools  and  feedback  performance  in
terms  of  OAC  use,  and  deﬁning  the  population  who  would
beneﬁt  from  VKA  (rather  than  NOAC)  treatment  [46]. Addi-
tional  efforts  are  needed  to  improve  the  time  in  therapeutic
range  for  patients  on  VKAs.
While  the  half-life  of  the  NOACs  is  relatively  short  and
their  anticoagulant  effect  has  largely  disappeared  after
1—2  days,  investigations  are  being  conducted  to  identify
speciﬁc  antidotes  to  reverse  their  effects  [46].  Andexanet
alfa,  designated  a  breakthrough  therapy  by  the  US  FDA,  is
being  investigated  as  an  antidote  to  factor  Xa  inhibitors  in
two  phase  3  studies  (Andexanet  Alfa  a  Novel  Antidote  to
the  Anticoagulant  Effects  of  fXA  Inhibitors  [ANNEXA]).  The
results  for  ANNEXA-A  were  presented  at  the  2014  Ameri-
can  Heart  Association  Congress,  and  showed  that  andexanet
alfa  administration  was  well  tolerated  in  older  subjects  (age
55  to  73  years),  and  met  all  of  the  pre-speciﬁed  primary
and  secondary  efﬁcacy  endpoints  (all  P  <  0.0001).  All  of  the
andexanet-treated  patients  had  ≥  90%  reversal  of  anti-fXa
activity  and  restoration  of  thrombin  generation  to  base-
line  (pre-anticoagulant)  levels.  There  was  a  near-complete
normalization  of  all  coagulation  variables  measured  within
2  minutes  of  completion  of  infusion.  A  phase  3  study  will
aim  to  demonstrate  that  prolonged  reversal  can  be  sus-
tained  with  continuous  infusion  after  bolus  administration
[46].
Study limitations
The  LPD  database  provides  representative  data  from
patients  treated  in  practice  and  as  such  is  not  subject  to
ascertainment  bias.  However,  several  limitations  must  be
noted.  The  data  are  prone  to  information  bias  as  no  restric-
tions  were  imposed  on  GPs  in  terms  of  the  data  collection.
The  information  collected  is  restricted  to  GP  practices,
and  excludes  any  management  outside  of  primary  care  by,
for  example,  cardiologist  or  other  specialists.  However,  in
view  of  the  12-month  follow-up,  which  included  prescription
renewal  data,  patients  are  unlikely  to  have  been  incorrectly
classiﬁed  in  terms  of  the  various  treatment  groups.  Informa-
tion  on  contraindications  to  OAC  therapy  or  patient  refusal551
o  take  therapy  was  not  available,  so  the  proportions  of
atients  who  were  under-treated  or  who  received  no  treat-
ent  are  likely  to  be  slightly  elevated.  Data  were  collected
uring  GP  consultations  and  it  is  unlikely  that  they  were  able
o  collect  all  determinants  for  prescription  choice.  Varia-
les  that  may  inﬂuence  anticoagulant  prescription  may  have
een  unavailable.  Finally,  the  survey  was  completed  in  2011,
efore  publication  of  the  updated  ESC  guidelines  for  AF  [7],
nd  the  results  may  not  be  reﬂective  of  current  practices.
onclusions
n  this  large  study  based  on  data  from  the  French  pri-
ary  care  setting,  four  out  of  ﬁve  patients  diagnosed  with
F  should  beneﬁt  from  stroke  prophylaxis.  Around  45%  of
hromboembolic  high-risk  patients  either  are  not  treated  or
re  inadequately  treated.  Better  compliance  with  evidence-
ased  guidelines  and  improved  collaboration  between  GPs
nd  cardiologists  is  needed  in  order  to  reduce  the  burden  of
troke  in  the  AF  population.
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